Watching
ABSI · Absci Corporation
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 22 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A weekly close below $7.50, under the $8.25 close of 16 October 2026 and far below the $11.62 52-week high. Separately, the case breaks if interim ABS-201 data show no hair-count gain over placebo, or if no interim efficacy data appear by 31 December 2026.
Last pick Medium conviction, to : −5.5% against the S&P 500's +1.9%. Trailed the S&P 500 · conviction cut below medium.
Catalyst (in 20 days)
How picks are graded →The thesis
Absci Corporation's shares still turn on one result: whether its antibody ABS-201 grows human hair better than placebo. The company guides the interim proof-of-concept readout from its HEADLINE trial to the second half of 2026. A hair-count miss, or no efficacy data by 31 December 2026, breaks the case. The 12 November 2026 quarterly report is the next point where Absci can confirm or move that window.
The shares have recovered since the 19 October 2026 note, with no new company disclosure behind the move. Adjusted daily closes show $8.25 on 16 October 2026 and $10.04 on 21 October 2026, which leaves the price 13.6% below the $11.62 52-week high. MarketBeat tied a 5.8% gain on 19 October 2026 to KeyBanc's target increase to $20 from $16, and said trading volume that day was 92% below average. Searches of company news and coverage found no Absci release dated 20 October 2026 or 21 October 2026.
The narrative is maturing: the hair-loss readout is widely followed, and new attention since the 24 September 2026 endometriosis trial outline has come from analyst target changes, options activity and the 13 October 2026 earnings-date notice. Absci has published no hair-count data since the blinded safety release of 24 June 2026. The rating stays where it was because the price recovery adds no fact about the drug.
Bullish and bearish views on Absci Corporation
The bull case on Absci Corporation (ABSI), in brief: Cash lasts well past the readout. The bear case: Efficacy has not been tested yet.
Bull case
- Cash lasts well past the readout. Absci reported $201.1 million in cash, cash equivalents and marketable securities at 30 June 2026. On 11 August 2026, the company said this funds operations into the second half of 2028.
- The drug may need only occasional doses. On 24 June 2026, Absci reported blinded data from 32 healthy participants given single intravenous doses of 150 to 1,800 mg. There were no serious adverse events, and the estimated half-life was at least 65 days, which the company says could support two or three doses over six months.
- Analyst targets keep rising. KeyBanc raised its target to $20 from $16 on 16 October 2026, and JPMorgan raised its target to $15 from $14 on 12 October 2026, per TipRanks headlines carried by CNN. H.C. Wainwright reiterated Buy with a $16 target on 12 October 2026, per Benzinga. MarketBeat cited an average target of $14.56 on 19 October 2026.
- A large drugmaker invested. Absci's 11 August 2026 release confirmed a $100 million share offering in June 2026 that included a $40 million strategic investment from Eli Lilly.
- A second disease is planned. On 24 September 2026, Absci outlined STORYLINE, a placebo-controlled Phase 2 trial of ABS-201 in endometriosis with about 150 patients in 10 or more countries, starting in mid-2027.
Bear case
- Efficacy has not been tested yet. The 24 June 2026 release covered blinded safety and pharmacokinetic data, meaning how the drug moves through the body. The hair-regrowth evidence Absci cites comes from mouse studies, and the valuation rests on whether it holds in people.
- The business has almost no revenue. Absci reported second-quarter 2026 revenue of $0.3 million against a net loss of $33.2 million on 11 August 2026.
- The price swings without company news. Adjusted daily closes went from $11.53 on 5 October 2026 to $8.25 on 16 October 2026 and back to $10.04 on 21 October 2026. None of those moves came with a clinical or financial disclosure from Absci.
- The timing guidance is a window. The company guides only to the second half of 2026, with full proof-of-concept data in early 2027. Any slip pushes the deciding event outside the next three months.
Price setup
Adjusted daily closes show $11.53 on 5 October 2026, $8.94 on 8 October 2026, $10.16 on 9 October 2026, $9.10 on 13 October 2026, $8.25 on 16 October 2026 and $10.04 on 21 October 2026. The shares rose 32.8% over the three months to 21 October 2026. The 14-day relative strength index (RSI), a momentum gauge, was 45.9 on 21 October 2026, up from 42.3 on 16 October 2026 and still neutral.
The $8.25 close of 16 October 2026 is the recent low, and the $11.62 52-week high is the prior peak. A weekly close below $7.50 would put the shares under that October low by a clear margin, ahead of any efficacy data.
Crowding signals are mixed. Benzinga listed Absci among health-care names with large options trades on 12 October 2026. MarketBeat reported that the 19 October 2026 gain came on light volume. The 12 November 2026 earnings date sits three weeks out, and the interim readout could arrive at any point before year-end.
Catalysts, next 30 days
- 12 November 2026, before market open: third-quarter 2026 results, with a conference call at 8:00 a.m. Eastern Time, per Absci's 13 October 2026 release. The report shows whether interim HEADLINE data are still guided to the second half of 2026 and updates cash against the runway into the second half of 2028.
- By 31 December 2026 (guided window, no fixed date): interim HEADLINE proof-of-concept data, including target-area hair count. This is the event that decides the case; it falls outside the 30-day window unless Absci releases it early.
What would change the view
The case breaks if interim HEADLINE data show no gain in target-area hair count over placebo. It also breaks on timing if the 12 November 2026 report moves the interim readout into 2027, or if no interim efficacy data appear by 31 December 2026.
On price, a weekly close below $7.50 would show the shares falling under the 16 October 2026 low before any efficacy result, which would end the thesis. A new share sale disclosed before the readout would weaken the case, since the company guided runway into the second half of 2028 on 11 August 2026.
The rating would move up only on new evidence: interim hair-count data that separate from placebo, or a firm release date inside the next three months.
What it trades with
Absci trades on its own clinical news more than on the market. Its moves in October 2026 lined up with analyst target changes, an earnings-date notice and options activity rather than with any index. MarketBeat linked a 9% gain on 22 September 2026 to Novo Nordisk's plans to enter the hair-loss market, so news from larger drugmakers in hair loss can move the shares. Eli Lilly's $40 million investment of June 2026 ties sentiment loosely to Lilly, though no licensing terms have been disclosed.
Notes
- Absci is pre-commercial: second-quarter 2026 revenue was $0.3 million against a $33.2 million net loss, so the valuation rests on clinical assets.
- The runway into the second half of 2028 is management guidance from 11 August 2026 and assumes current spending plans hold.
- The ABS-201 Phase 1 single-dose cohorts were dosed intravenously, at 150, 450, 900 and 1,800 mg, in healthy adult participants.
- Eli Lilly's $40 million was a strategic investment in the June 2026 offering; no licensing terms have been disclosed.
- The interim HEADLINE readout has no fixed release date; the company guides only to the second half of 2026, with full proof-of-concept data in early 2027.
Related · shared themes
HALO
Halozyme Therapeutics, Inc.
Halozyme Therapeutics' royalty stream is still compounding, helped by argenx's $1.721 billion third-quarter Vyvgart sales reported 22 October 2026. Halozyme's report, expected about 2 November 2026, shows whether 2026 royalty guidance of $1.220–1.245 billion holds or rises.
LLY
Eli Lilly and Company
Eli Lilly's tirzepatide growth and rising analyst targets hold the shares 1% below their record close; the 29 October 2026 third-quarter report decides whether revenue clears a Street bar set above Lilly's $85–87 billion 2026 guidance.
ACHV
Achieve Life Sciences, Inc.
Achieve Life Sciences' smoking-cessation drug cytisinicline was rejected on 20 June 2026 only over a former manufacturer's plant, and one-year data released on 21 October 2026 showed a 31.2% quit rate. A fourth-quarter 2026 refiling naming Adare as manufacturer, which the ~10 November 2026 report should confirm, decides the case.
ALVO
Alvotech
Alvotech's shares turn on FDA approval of its Simponi and Eylea biosimilars, AVT05 and AVT06, expected in Q4 2026 after three favourable FDA actions at its Reykjavik plant since July. The 11 November 2026 Q3 report shows first whether the $650–700 million FY2026 revenue guidance holds.
See also · stocks to watch